Drug Profile

Taspitimagene advec - Rznomics

Alternative Names: Ad-ECRT-122T; RZ-001

Latest Information Update: 24 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rznomics
Class Antineoplastics; Gene therapies; Immunotherapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Liver cancer
New Molecular Entity No

Highest Development Phases

Phase I/II Glioblastoma; Liver cancer

Most Recent Events

15 Jun 2026 Efficacy and adverse events data from a phase I/IIa trial in Glioblastoma released by Rznomics
08 May 2026 RZ 001 receives Regenerative Medicine Advanced Therapy (RMAT) status for Liver cancer in USA
22 Apr 2026 Efficacy and adverse event data from phase Ib/IIa trial in Liver cancer presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com